Knowledge and cardiovascular disease risk among patients are taking cardiovascular related medications
Keywords:
Knowledge, Cardiovascular Disease Risk, Questionnaire, Community pharmacyAbstract
In pharmacy environments it is increasingly necessary to develop strategies to assess and improvepatient’s knowledge about cardiovascular disease (CVD). The aim of this study was to investigate therelationship between knowledge and CVD risk. A 10 question interviewer-controlled cross sectionalsurvey was carried out over a period of 15 days, about the knowledge and the CVD risk, in patientsattending 6 community pharmacies in Granada, Sevilla, and Malaga (Andalucia-Spain). In the statisticalanalyses, the Chi square test was used to compare proportions, and T Student test to compare means.A total of 257 patients took part in the survey; age (years): 60.9 + 10.8, sex (male): 35.8%, currentsmokers: 13.2%, a personal history of hypertension (79.0%), high cholesterol levels (42.4%), type 2 diabetes (19.5%), and CVD (22.6%). CVD risk was: Low 35.8%, mild - moderate: 21.0%, and high:43.2%. The degree of knowledge was 5.8 + 1.8 (CI95%:5.6-6.1), and was assessed as being adequatein 60.7%; (CI95%:54.7-66.7%). Age (younger patients), a high level of education, and the regularpractice of physical exercise, together with a positive patient perception of normality or control ofcardiovascular risk factors, were associated with better or higher knowledge of cardiovascular risk.However, no significant differences in patient’s knowledge was found among patients presenting differentdegrees of total CVD risk (p>0.05). Adequate patient’s knowledge about CVD risk is associated withyounger age, a high educational level, exercise practice, and perceptions of normality or control ofcardiovascular risk factors, but it is not related to the total CVD risk.Downloads
References
Instituto Nacional de Estadística de España. España en cifras 2003-2004. Salud. Defunciones según las causas de muerte más significativas. Disponible en www.ine.es/especif/especifes/especif0304.htm
Junta de Andalucía, Consejería de Salud. Riesgo Vascular: Proceso Asistencial Integrado. Sevilla, Consejería de Salud, 2003. 241 p.
Gavin JR 3rd, Peterson K, Warren-Boulton E; National Diabetes Education Program. Reducing cardiovascular disease risk
in patients with type 2 diabetes: a message from the National Diabetes Education Program. Am Fam Physician 2003;
:1569-1574.
Brotons C, Royo-Bordonada MA, Álvarez-Sala L, et al. Comité Español Interdisciplinario para la Prevención Cardiovascular
(CEIPC). Adaptación Española de la Guía Europea de Prevención Cardiovascular. Clin Invest Arteriosc 2005; 17:19-33.
Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362:1527–
Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs:
analysis of 354 randomised trials. BMJ 2003; 326:1427-1431.
Pini R, Cavallini MC, Bencini F, et al. Cardiac and Vascular Remodeling in Older Adults With Borderline Isolated Systolic
Hypertension: The ICARe Dicomano Study. Hypertension 2001; 38:1372-1376.
LaRosa JC, He J, Vupputuri S. Effects of statins on risk of coronary disease: a meta-analysis of randomized control trials.
JAMA 1999; 282:2340-2346.
Pignone M, Phillips C, Mulrow C. Use of lipid lowering drugs for primary prevention of coronary heart disease: metaanalysis
of randomized trials. BMJ 2000; 321:983-986.
Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major
vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004; 363:757–767.
Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic hearth disease, and stroke: systematic review and meta-analysis. BMJ 2003; 326:1423-1427.
Huang ES, Meigs JB, Singer DE: The effect of interventions to prevent cardiovascular disease in patients with type 2
diabetes mellitus. Am J Med 2002; 111:633–642.
Wilson K, Gibson N, Willian A, Cook D. Effect of smoking cessation on mortality after myocardial infarction: metaanalysis of cohort studies. Arch Intern Med 2000; 160:939-944.
Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA 2003; 290:86-97.
Ministerio de Sanidad y Consumo – España. Instituto Información S.N.S. Encuesta Nacional de Salud 2001: Primera oleada Noviembre 2003. Disponible en: www.msc.es/Diseno/informacionProfesional/profesional_sistemas_informacion.htm.
Downloads
Published
How to Cite
Issue
Section
License
The articles, which are published in this journal, are subject to the following terms in relation to the rights of patrimonial or exploitation:
- The authors will keep their copyright and guarantee to the journal the right of first publication of their work, which will be distributed with a Creative Commons BY-NC-SA 4.0 license that allows third parties to reuse the work whenever its author, quote the original source and do not make commercial use of it.
b. The authors may adopt other non-exclusive licensing agreements for the distribution of the published version of the work (e.g., deposit it in an institutional telematic file or publish it in a monographic volume) provided that the original source of its publication is indicated.
c. Authors are allowed and advised to disseminate their work through the Internet (e.g. in institutional repositories or on their website) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).
